These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28431161)

  • 41. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.
    Shinmi D; Nakano R; Mitamura K; Suzuki-Imaizumi M; Iwano J; Isoda Y; Enokizono J; Shiraishi Y; Arakawa E; Tomizuka K; Masuda K
    Cancer Med; 2017 Apr; 6(4):798-808. PubMed ID: 28211613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preparation and characterization of anti-anti-idiotypic monoclonal antibody ("Ab1-like Ab3") in relation to carcinoembryonic antigen.
    Tsujisaki M; Masuya J; Okada Y; Jinnohara T; Sasaki S; Yachi A; Imai K
    J Clin Lab Anal; 2002; 16(6):279-89. PubMed ID: 12424800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution.
    Murakami M; Kuroki M; Arakawa F; Haruno M; Kuwahara M; Ozaki H; Senba T; Matsuoka Y
    Immunol Invest; 1996; 25(1-2):23-35. PubMed ID: 8675232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Binding studies on two different monoclonal antibodies raised against CEA.
    Rogers GT; Rawlins GA; Kardana A; Gibbons AR
    Eur J Cancer Clin Oncol; 1983 May; 19(5):629-39. PubMed ID: 6683635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based engineering of a monoclonal antibody for improved solubility.
    Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
    Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
    Yazaki PJ; Lee B; Channappa D; Cheung CW; Crow D; Chea J; Poku E; Li L; Andersen JT; Sandlie I; Orcutt KD; Wittrup KD; Shively JE; Raubitschek A; Colcher D
    Protein Eng Des Sel; 2013 Mar; 26(3):187-93. PubMed ID: 23175797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
    Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
    Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours.
    Durrant LG; Denton GW; Jacobs E; Mee M; Moss R; Austin EB; Baldwin RW; Hardcastle JD; Robins RA
    Int J Cancer; 1992 Mar; 50(5):811-6. PubMed ID: 1544714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody affinity maturation in vitro using unconjugated peptide antigen.
    Iwai H; Oztürk B; Ihara M; Ueda H
    Protein Eng Des Sel; 2010 Apr; 23(4):185-93. PubMed ID: 20123883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal, anti-domain and anti-peptide antibodies assign the molecular weight 160,000 granulocyte membrane antigen of the CD66 cluster to a mRNA species encoded by the biliary glycoprotein gene, a member of the carcinoembryonic antigen gene family.
    Stoffel A; Neumaier M; Gaida FJ; Fenger U; Drzeniek Z; Haubeck HD; Wagener C
    J Immunol; 1993 Jun; 150(11):4978-84. PubMed ID: 8496599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutational analysis of the virus and monoclonal antibody binding sites in MHVR, the cellular receptor of the murine coronavirus mouse hepatitis virus strain A59.
    Wessner DR; Shick PC; Lu JH; Cardellichio CB; Gagneten SE; Beauchemin N; Holmes KV; Dveksler GS
    J Virol; 1998 Mar; 72(3):1941-8. PubMed ID: 9499047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
    Pavoni E; Flego M; Dupuis ML; Barca S; Petronzelli F; Anastasi AM; D'Alessio V; Pelliccia A; Vaccaro P; Monteriù G; Ascione A; De Santis R; Felici F; Cianfriglia M; Minenkova O
    BMC Cancer; 2006 Feb; 6():41. PubMed ID: 16504122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design.
    Casset F; Roux F; Mouchet P; Bes C; Chardes T; Granier C; Mani JC; Pugnière M; Laune D; Pau B; Kaczorek M; Lahana R; Rees A
    Biochem Biophys Res Commun; 2003 Jul; 307(1):198-205. PubMed ID: 12850000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Affinity Improvement of a Cancer-Targeted Antibody through Alanine-Induced Adjustment of Antigen-Antibody Interface.
    Yamashita T; Mizohata E; Nagatoishi S; Watanabe T; Nakakido M; Iwanari H; Mochizuki Y; Nakayama T; Kado Y; Yokota Y; Matsumura H; Kawamura T; Kodama T; Hamakubo T; Inoue T; Fujitani H; Tsumoto K
    Structure; 2019 Mar; 27(3):519-527.e5. PubMed ID: 30595454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis.
    Bès C; Briant-Longuet L; Cerutti M; Heitz F; Troadec S; Pugnière M; Roquet F; Molina F; Casset F; Bresson D; Péraldi-Roux S; Devauchelle G; Devaux C; Granier C; Chardes T
    J Biol Chem; 2003 Apr; 278(16):14265-73. PubMed ID: 12566463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.
    Horwacik I; Kurciński M; Bzowska M; Kowalczyk AK; Czaplicki D; Koliński A; Rokita H
    Int J Mol Med; 2011 Jul; 28(1):47-57. PubMed ID: 21455557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetic analysis of the effect on Fab binding of identical substitutions in a peptide and its parent protein.
    Choulier L; Rauffer-Bruyère N; Ben Khalifa M; Martin F; Vernet T; Altschuh D
    Biochemistry; 1999 Mar; 38(12):3530-7. PubMed ID: 10090739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.